Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Total Liabilities (2024 - 2025)

Historic Total Liabilities for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $36.2 million.

  • Prelude Therapeutics' Total Liabilities fell 1119.91% to $36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.2 million, marking a year-over-year decrease of 1119.91%. This contributed to the annual value of $44.1 million for FY2024, which is N/A changed from last year.
  • Per Prelude Therapeutics' latest filing, its Total Liabilities stood at $36.2 million for Q3 2025, which was down 1119.91% from $39.1 million recorded in Q2 2025.
  • Over the past 5 years, Prelude Therapeutics' Total Liabilities peaked at $44.1 million during Q4 2024, and registered a low of $36.2 million during Q3 2025.